Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396381 · ClinicalTrials.gov registry record · NA
Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks
A NA study, sponsored by Philip Morris Products S.A..
- Completed
- Registry status
- NA
- Development phase
- 1,039
- Enrollment target
NCT02396381: Completed NA study, sponsored by Philip Morris Products S.A..
NCT02396381 is a NA study that has completed, run by Philip Morris Products S.A.. The registered enrollment target is 1,039 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02396381, a NA study, has completed, sponsored by Philip Morris Products S.A..
- COMPLETED
- Registry status
- NA
- Development phase
- 1,039 participants
- Enrollment target
Study Summary
The aim of the study is to demonstrate clinical, biological and functional health changes in smokers switching to the candidate modified risk tobacco product: Tobacco Heating System 2.2 (THS 2.2) as compared to smokers continuing smoking their conventional cigarettes (CC) over a 26-week period. To characterize the study as successful, at least 5 clinical risk endpoints should move in the direction of smoking cessation and these results would be statistically significant. The main analysis will be defined a priori (using the Hailperin-Ruger approach) and will be made between THS 2.2 use and CC use as "per actual product used" and product use categories.
Primary Outcome
Concentrations measured in serum. Geometric Least Squares means are provided as descriptive statistics.
Interventions
- OTHER CC
- OTHER THS 2.2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,039 participants |
| Start Date | 2015-03-12 |
| Est. Completion | 2017-08-01 |
| Phase | NA |
What the finished NCT02396381 record still lists
NCT02396381 is an interventional study that assigns participants to a tested intervention. Its 1,039 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 2 interventions - of which CC is the first listed.
NCT02396381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02396381 about?
NCT02396381 is a clinical study titled "Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks". The aim of the study is to demonstrate clinical, biological and functional health changes in smokers switching to the candidate modified risk tobacco product: Tobacco Heating System 2.2 (THS 2.2) as compared to smokers continuing smoking their conventional cigarettes (CC) over a 26-week period. To ...
What is the current status of trial NCT02396381?
This trial is currently completed. It is a NA study. The enrollment target is 1,039 participants. The study started on 2015-03-12. Estimated completion is 2017-08-01.
What interventions are being tested in trial NCT02396381?
The interventions under investigation include: CC (OTHER), THS 2.2 (OTHER).
Who is sponsoring clinical trial NCT02396381?
This trial is sponsored by Philip Morris Products S.A., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02396381's enrollment target sits among peer trials
1,039 101st of 2000 higher than 1,900 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
- NCT06661720 · 1,040 participants · Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- NCT07345767 · 1,038 participants · NA
Hypknowledge Nationwide Sleep Extension
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI